

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

Γ	APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
•	10/750,213	01/02/2004		Michael L. Vazquez	101765.00005 (2703/9/DIV)	6652	
	22907	7590	03/15/2005		EXAM	EXAMINER	
	BANNER &	WITCO	OFF	O SULLIVA	O SULLIVAN, PETER G		
	1001 G STRE	ET N W			ART UNIT	PAPER NUMBER	
	SUITE 1100	D.C	20001				
	WASHINGTON, DC 20001				1621		

DATE MAILED: 03/15/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

				<u> </u>						
		Application No.	Applicant(s)	C						
		10/750,213	VAZQUEZ ET AL.							
	Office Action Summary	Examiner	Art Unit							
		Peter G. O'Sullivan	1621							
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply									
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).										
Status										
1)[	Responsive to communication(s) filed on									
2a)□	•	is action is non-final.	•							
3)□										
Disposition of Claims										
5) 6) 7)	4)⊠ Claim(s) 124-129 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration.  5)□ Claim(s) is/are allowed.  6)□ Claim(s) is/are rejected.									
Applicat	ion Papers									
9)☐ The specification is objected to by the Examiner.										
10)	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.									
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
11)	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority (	ınder 35 U.S.C. § 119									
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>										
Attachmen	t(s)									
1) Notice 2) Notice 3) Inform	te of References Cited (PTO-892) se of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/06 or No(s)/Mail Date	4) Interview Summ Paper No(s)/Mai  5) Notice of Informa 6) Other:								

Application/Control Number: 10/750,213

Art Unit: 1621

Claims 124-129 generic to a plurality of disclosed patentably distinct species comprising, for example, compounds which are heterocyclic or non-heterocyclic.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Again, applicants are required to elect a single disclosed species, <u>i.e. a single</u> <u>disclosed compound.</u>

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication should be directed to Peter G. O'Sullivan at telephone number (571)272-0642.

PETER O'SULLIVAN PRIMARY EXAMINER GROUP 1200